Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time
Manufacturing Inspection Delays Could Impact Decision Due 27 March
Celgene shareholders get a payout from BMS if ide-cel and two other drugs are approved by specific deadlines • Source: Shutterstock 
